<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-80518</identifier>
<setSpec>0211-139X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Reliability of different criteria in identifying end-of-life trajectory of patients with chronic medical diseases. PALIAR Project</dc:title>
<dc:description xml:lang="en">Introduction. It is a challenge to reliably identify the end-of-life trajectory in patients with advanced-stage chronic medical conditions. This makes advanced supportive care planning and transition from survival to comfort objectives more difficult in these emergent patient populations. Objectives. To evaluate the sensitivity (Se), specificity (Sp), positive predictive values (PPV) and negative (NPV), and validity index (IV) of NHO criteria for terminal medical conditions, PPI and ECOG in patients with advanced heart, lung, liver, kidney and/or neurological diseases, and to build and validate an accurate index to determine this border-line. Methods. A multicentre prospective cohort study, with inclusion of patients with the predefined advanced medical diseases. Demographic, clinical, care, stratification and staging of disease(s), functional, analytical, NHO criteria, ECOG, PPS and PPI data collection; The end-point (death) will be assessed 180 days after inclusion. Analysis of Se, Sp, PPV, NPV, and IV of the NHO criteria, ECOG scale and PPI at 30, 60, 90, 120, 150 and 180 days. Derivation of PALIAR Index, after multivariate analysis and appropriate weighting of risk factors (beta of risk factor/lowest beta of the model), and validation in the validation cohort, and in the historical PROFUND cohort. Results. The project is still ongoing, with 50 investigators from 33 hospitals throughout Spain, who have already included 1138 patients (92.5% during hospital admissions, 51.4% of them are male, with a mean age of 78.5 years). Mean inclusion chronic diseases were 1.4 per patient (44.5% of patients suffered chronic neurological diseases, 38.6% with heart failure, 34.2% with lung diseases, 12% with liver diseases, and 6.5% with renal diseases)...(AU)</dc:description>
<dc:creator>Fernández-López, Auxiliadora</dc:creator>
<dc:creator>Moreno-Gaviño, Lourdes</dc:creator>
<dc:creator>Ollero-Baturone, Manuel</dc:creator>
<dc:creator>Ramos-Cantos, Carmen</dc:creator>
<dc:creator>Nieto-Martín, María Dolores</dc:creator>
<dc:creator>Hernández-Quiles, Carlos</dc:creator>
<dc:creator>Murcia-Zaragoza, José</dc:creator>
<dc:creator>Fernández-Moyano, Antonio</dc:creator>
<dc:creator>Bernabeu-Wittel, Máximo</dc:creator>
<dc:creator>Ruiz-Cantero, Alberto</dc:creator>
<dc:creator>Barón-Franco, Bosco</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. Existe incertidumbre para identificar adecuadamente la trayectoria del final de la vida en pacientes con enfermedades médicas crónicas en fases avanzadas, hecho que dificulta en muchos casos la planificación de servicios y el proceso de transición, de unos objetivos de supervivencia a unos terapéuticos de calidad de vida. Objetivos. Evaluar la sensibilidad, especificidad, valores predictivos positivo y negativo, e índice de validez de los criterios de enfermedad médica terminal del National Hospice Organization estadounidense, la Palliative Prognostic Index y la Eastern Cooperative Oncology Group (ECOG) en pacientes con enfermedades cardíacas, neumológicas, hepáticas, renales y/o neurológicas en estadío avanzado; y construir-validar un índice específico para determinar con mayor certidumbre esta frontera. Métodos. Estudio de cohortes prospectivas multicéntrico con inclusión de pacientes con criterios predefinidos de enfermedad avanzada en órganos comentados. Recogida de datos demográficos, clínico-asistenciales, de estratificación y estadiaje de enfermedad(es), funcionales, analíticos, criterios de la National Hospice Organization, ECOG, valores predictivos positivos y Palliative Prognostic Index; y de la variable final (fallecimiento) a los 180 días de la inclusión. Análisis de sensibilidad, especifidad, valores predictivos positivos, negativos e índice de validez de los criterios de la National Hospice Organization, escala ECOG y Palliative Prognostic Index a los 30, 60, 90, 120, 150 y 180 días. Derivación, si procede, del indice PALIAR, tras análisis multivariante y ponderación de los factores de riesgo (beta del f. riesgo/beta menor del modelo) y posterior validación en cohorte de validación y cohorte histórica PROFUND...(AU)</dc:description>
<dc:source>Rev. esp. geriatr. gerontol. (Ed. impr.);45(4): 203-212, jul.-ago.2010. tab, ilus</dc:source>
<dc:identifier>ibc-80518</dc:identifier>
<dc:title xml:lang="es">Precisión de los criterios definitorios de pacientes con enfermedades médicas no neoplásicas en fase terminal. Proyecto PALIAR</dc:title>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d10353^s22083</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d28603</dc:subject>
<dc:subject>^d50061</dc:subject>
<dc:subject>^d50060</dc:subject>
<dc:subject>^d10353^s22066</dc:subject>
<dc:subject>^d14105^s22049</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d10353^s22045</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d28606</dc:subject>
<dc:subject>^d14105^s22066</dc:subject>
<dc:subject>^d14105^s22045</dc:subject>
<dc:subject>^d33200^s22083</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:type>article</dc:type>
<dc:date>201008</dc:date>
</metadata>
</record>
</ibecs-document>
